OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Kong, Young-Yun; Yoshida, Hiroki; Sarosi, Ildiko; Tan, Hong-Lin; Timms, Emma; Capparelli, Casey; Morony, Sean; Oliveira-dos-Santos, Antonio J.; Van, Gwyneth; Itie, Annick; Khoo, Wilson; Wakeham, Andrew; Dunstan, Colin R.; Lacey, David L.; Mak, Tak W.; Boyle, William J.; Penninger, Josef M.

Affiliations

¹Amgen Institute, Ontario Cancer Institute, and the Departments of Medical Biophysics and Immunology, University of Toronto, 620 University Avenue, Toronto, Ontario M5G 2C1, Canada

²Department of Pathology, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1789, USA

³Department of Cell Biology, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1789, USA

Abstract

The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.

Links

DOI: 10.1038/16852

PubMed: 9950424

WoS: 000078324600040

History

Received: 1998-10-01

Accepted: 1998-12-04

Cited Works (5)

Year	Entry
1997	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ; Amgen EST Program. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. April 18, 1997;89(2):309-319.
1995	Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. NEJM. February 2, 1995;332(5):305-311.
1998	Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. April 17, 1998;93(2):165-176.
1998	Yasuda H, Shima N, Akagawa NN, Yamaguchi K, Kinosaki M, Mochizuki S-I, Omoyasu AT, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Igashio KH, Udagawa N, Tkahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. March 31, 1998;95(7):3597-3602.
1990	Yoshida H, Hayashi S-I, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S-I. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. May 31, 1990;345(6274):442-444.

Cited By (58)

Year	Entry
2011	Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121-145.
2020	Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82:485-506.
2008	Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. May 15, 2008;473(2):139-146.
2007	Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. February 2007;40(2):251-264.
2011	Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. April 2011;48(4):677-692.
2020	Omata Y, Frech M, Lucas S, Primbs T, Knipfer L, Wirtz S, Kadono Y, Saito T, Tanaka S, Sarter K, Schett G, Zaiss MM. Type 2 innate lymphoid cells inhibit the differentiation of osteoclasts and protect from ovariectomy-induced bone loss. Bone. July 2020;136:115335.
2020	Usategui-Martín R, Lendinez-Tortajada V, Pérez-Castrillón JL, Briongos-Figuero L, Abadía-Otero J, Martín-Vallejo J, Lara-Hernandez F, Chaves FJ, García-Garcia AB, Martín-Escudero JC. Polymorphisms in genes involved in inflammation, the NF-kB pathway and the renin-angiotensin-aldosterone system are associated with the risk of osteoporotic fracture: the Hortega follow-up study. Bone. September 2020;138:115477.
2021	Andes F, Adam S, Hahn M, Aust O, Frey S, Grueneboom A, Nitschke L, Schett G, Steffen U. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog >Siglec-e control osteoclast activity and bone resorption. Bone. February 2021;143:115665.
2021	Monteiro AC, Bonomo A. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption. Bone. February 2021;143:115755.
2021	Schreuder WH, van der Wal JE, Lange J, van den Berg H. Multiple versus solitary giant cell lesions of the jaw: similar or distinct entities? Bone. August 2021;149:115935.
2022	Takegahara N, Kim H, Choi Y. RANKL biology. Bone. June 2022;159:116353.
2022	Ikeuchi T, Moutsopoulos NM. Osteoimmunology in periodontitis: a paradigm for Th17/IL-17 inflammatory bone loss. Bone. October 2022;163:116500.
2022	Elson A, Anuj A, Barnea-Zohar M, Reuven N. The origins and formation of bone-resorbing osteoclasts. Bone. November 2022;164:116538.
2022	Sobacchi C, Abinun M. Osteoclast-poor osteopetrosis. Bone. November 2022;164:116541.
2023	O'Donohue AK, Xiao Y, Lee LR, Schofield T, Cheng TL, Munns CF, Baldock PA, Schindeler A. Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density. Bone. February 2023;167:116636.
2023	Grčević D, Sanjay A, Lorenzo J. Interactions of B-lymphocytes and bone cells in health and disease. Bone. March 2023;168:116296.
2021	Wallimann A, Hildebrand M, Groeger D, Stanic B, Akdis CA, Zeiter S, Richards RG, Moriarty TF, O’Mahony L, Thompson K. An exopolysaccharide produced by Bifidobacterium longum 35624® inhibits osteoclast formation via a tlr2-dependent mechanism. Calcif Tiss Int. May 2021;108(5):654-666.
2002	Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J-i, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. December 1, 2002;3(6):889-901.
1999	Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. June 1999;20(3):345-357.
2000	Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. April 2000;21(2):115-137.
2010	Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. August 13, 2010;285(33):25103-25108.
2019	Li Y, Shi Z, Jules J, Chen S, Kesterson RA, Zhao D, Zhang P, Feng X. Specific RANK cytoplasmic motifs drive osteoclastogenesis. J Bone Miner Res. October 2019;34(10):1938-1951.
2020	Kittaka M, Yoshimoto T, Schlosser C, Rottapel R, Kajiya M, Kurihara H, Reichenberger EJ, Ueki Y. Alveolar bone protection by targeting the SH3BP2‐SYK axis in osteoclasts. J Bone Miner Res. February 2020;35(2):382-395.
2023	Stein M, Elefteriou F, Busse B, Fiedler IA, Kwon RY, Farrell E, Ahmad M, Ignatius A, Grover L, Geris L, Tuckermann J. Why animal experiments are still indispensable in bone research: a statement by the European Calcified Tissue Society. J Bone Miner Res. August 2023;38(8):1045-1061.
2003	Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. April 2003;111(8):1221-1230.
2020	Hongo H, Hasegawa T, Saito M, Tsuboi K, Yamamoto T, Sasaki M, Abe M, de Freitas PHL, Yurimoto H, Udagawa N, Li M, Amizuka N. Osteocytic osteolysis in PTH-treated wild-type and Rankl^−/− mice examined by transmission electron microscopy, atomic force microscopy, and isotope microscopy. J Histochem Cytochem. October 2020;68(10):651-668.
2002	Seeman E. Pathogenesis of bone fragility in women and men. Lancet. May 25, 2002;359(9320):1841-1850.
2011	Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. April 9, 2011;377(9773):1276-1287.
2011	Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. November 2011;17(10):1235-1242.
2013	Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. September 2013;9(9):522-536.
2003	Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. August 2003;4(8):638-649.
1999	Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. November 18, 1999;402(6759):304-309.
2003	Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. May 15, 2003;423(6937):337-342.
2020	Koide M, Yamashita T, Murakami K, Uehara S, Nakamura K, Nakamura M, Matsushita M, Ara T, Yasuda H, Penninger JM, Takahashi N, Udagawa N, Kobayashi Y. Sclerostin expression in trabecular bone is downregulated by osteoclasts. Sci Rep. 2020;10:13751.
2008	Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol. October 2008;19(5):459-466.
2017	Yumol JL. Determining If Lowering the Level of Dietary Calcium and Vitamin D in AIN-93G Diet Supports Normal Bone Development and Intestinal Integrity in Female CD-1 Mice [Master's thesis]. Brock University; November 2017.
2015	Scully N. Differentiation of Osteoblasts to Osteocytes in 3D Type I Collagen Gels: A Novel Tool to Study Osteocyte Responses to Mechanical Loading [PhD thesis]. Cardiff, UK: Cardiff University; April 2015.
2008	Willey JS. Radiation-Induced Osteoporosis: Bone Quantity, Architecture, and Increased Resorption Following Exposure to Ionizing Radiation [PhD thesis]. Clemson, SC: Clemson University; May 2008.
2020	Robinson ST. Bone Mechanobiology of Modeling and Remodeling and the Effect of Hematopoietic Lineage Cells [PhD thesis]. Columbia University; 2020.
2012	Slyfield CR Jr. The Biomechanics of Bone Turnover [PhD thesis]. Ithaca, NY: Cornell University; January 2012.
2014	Ye L. The Role of Sorting Nexin 10 (Snx10) in Control of Osteoclast Function and Regulation of Bone Homeostasis [PhD thesis]. Cambridge, MA: Harvard University; October 2014.
2011	Linares GR. Novel Molecules That Regulate Bone Formation and Bone Resorption [PhD thesis]. Loma Linda University; June 2011.
2014	Alshbool FZ. The Role of Claudins in Bone Metabolism [PhD thesis]. Loma Linda University; December 2014.
2009	Miller ES. The Role of E2f4 in Cell Cycle Exit and Bone Development [PhD thesis]. Cambridge, MA: Massachusetts Institute of Technology; June 2009.
2020	Simfia I. Estrogen Deficiency Alters the Mechanobiological Responses of Osteoblasts and Osteocytes [PhD thesis]. National University of Ireland Galway; April 2020.
2009	Litzenberger JB. The Role of Integrin Signaling in Bone Mechanotransduction [PhD thesis]. Stanford University; 2009.
2016	Yu Q. Applications of Human Bone Materials and Synthesized Biomaterials for Bone-Related Tissue Engineering [PhD thesis]. University of Akron; December 2016.
2012	Bhandari KH. Bone Targeting Salmon Calcitonin Analogues as Drug Delivery Systems for Bone Disease [PhD thesis]. Edmonton, AB: University of Alberta; 2012.
2013	Newa M. Antibody Mediated “Universal” Osteoclast Targeting Platform [PhD thesis]. Edmonton, AB: University of Alberta; 2013.
2013	Fowler TW. Activin Regulation of Osteoclast Formation, Motility, Function, and Survival [PhD thesis]. University of Arkansas for Medical Sciences; 2013.
2020	Pei S. Osteocyte Mechanosensing: Interstitial Fluid Flow, Cellular Response, and Turnover of Pericellular Matrix [PhD thesis]. University of Delaware; 2020.
2016	Takyar F. Osteoblastic EphrinB2 in Normal and Parathyroid Hormone (PTH)-Stimulated Bone Formation [PhD thesis]. University of Melbourne; June 2016.
2016	Vrahna C. Investigating the Effects of Downstream Parathyroid Hormone (PTH) Targets on Bone Strength and Quality [PhD thesis]. Melbourne, Australia: The University of Melbourne; December 2016.
2023	Kotsanti M. Evaluation of Mandibular Cortical Bone in a Healthy Paediatric Population [Master's thesis]. National and Kapodistrian University of Athens; 2023.
2019	Ma Y-HV. Regulation of Breast Cancer Cells’ Bone-Metastatic Potential by Mechanically Stimulated Osteocytes [PhD thesis]. University of Toronto; 2019.
2007	McDonald MM. The Role of the Osteoclast During Endochondral Ossification in a Rat Fracture Model [PhD thesis]. University of Technology Sydney (UTS); May 2007.
2014	Gandhi C. Effects of Matrix Advanced Glycation End Products on Human Osteoclast Resorption of Human Cortical Bone [Master's thesis]. San Antionio, TX: University of Texas at San Antonio; May 2014.
2013	Ausk BJ. Identifying the Origins of Bone Loss Induced by Transient Muscle Paralysis Using Novel MicroCT Image Registration Techniques [PhD thesis]. University of Washington; 2013.